SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Singleton who wrote (3701)2/1/1998 2:20:00 PM
From: Timothy Kross  Read Replies (1) of 6136
 
Peter: I visited the website for the Chicago conference and found six papers on Viracept that will be presented at the conference. One paper studied nelfinavir in conjunction with AZT and 3TC. There were three arms in the nelfinavir treatment groups: placebo, 500 mg TID, and 750 mg TID. They used various assays for HIV RNA including the bDNA assay (Chiron), and the experimental ultrasensitive PCR assay (Ultra-S). This new assay has a limit of detection down to 50 copies/ml. The study showed that at one year the nelfinavir 750mg TID, with AZT and 3TC showed that 62 % had undetectable viral DNA in their plasma, thus indicating almost a 3 log reduction in viral load that maintained itself for one year. At six months this group had a 66% undetectable viral load. It was also clear that the control group had only a 23% undetectable viral load, and that the nelfinavir 500 mg TID group had only a 35% undetectable viral load.

A second paper discussed BID dosing of Viracept with d4T and 3TC. The two group comparative trial compared Viracept 1250 mg BID to 750 mg TID. This European study looked at 279 3TC naive patients, but could have had other nucleoside antiretroviral therapy for less than six months at the time of the study. Mean baseline viral loads were 4.8 log 10. The study looked at viral loads at sixteen weeks between the two treatment arms. They concluded that both regimens were effective in suppressing viral load at the sixteen week point. The BID group had 83% complete suppression while the TID group had 78% complete suppression. They used an assay that was sensitive down to 400 copies/ml.
It looks that BID dosing works well. This is good news in my opinion for the stock. Of course, we do not yet have the similar comparison for indinavir at the BID dosing. Will continue the search!

Best regards,

Tim Kross
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News